18The timetable for the introduction of pharmaceutical patents in India under TRIPS ensures that if Indian drug prices rise in the remaining 1990s, it will not be for patent reasons. The earliest start of premium pricing for patented medicines will take place in the early years of the next decade. No significant effects are expected before 2005, as the weight of patented medicines on the Indian market will be too low to have an economic impact. 17To take into account the moderate pace of pharmaceutical innovation and barriers to market penetration of new medicines in India. Such an examination leads to the conclusion that no more than 15% of the Indian market will be covered by patents in terms of value at some point after 2005. The remaining 85% of the market will continue to be exposed to the effects of generic competition. Patented products will ultimately contribute to this generic pool themselves when their patents expire. 19 More important than the timing of patent protection, there will be basic checks and balances that will slow the impact of high prices on Indian pharmaceutical spending (see Box 2). These balances are as follows: This article is a nuanced understanding of the impact of the TRIPS Agreement on the pharmaceutical industry and the right to health. Since its inception, the TRIPS Agreement or the Agreement on Trade-Related Aspects of Intellectual Property Rights has affected intellectual property rights, particularly in developing countries.
The article measures the functioning of the pharmaceutical industry and interacts with the Indian Patent Act and its subsequent amendments. Abinaya K conducts a detailed analysis of practices such as “permanent patent updating”. It also offers alternatives such as compulsory licensing and price caps to balance and protect the consumer`s right to health as a whole. In its two motions filed in the Madras High Court under Section 226 in 2006, Novartis declared that Section 3(d) of the Patent Act was unconstitutional. It justified this by arguing that the section violated Article 14 of the Constitution and was also inconsistent with the TRIPS Agreement. 55The most difficult part is the position that the Indian government should take with regard to TRIPS and its impact on the pharmaceutical market. The subject is politico-economic and must be approached from both angles – economics and politics. [14] Sharma, Aayush. “India: Compulsory License: The Most Happening Section Of The Patents Act, 1970,” mondaq, October 15, 2015, www.mondaq.com/india/Intellectual-Property/435044/. Retrieved 14 April 2021. [15] “Economic Study 2020-2021” Indian budget, www.indiabudget.gov.in/economicsurvey/doc/echapter.pdf.
Accessed April 14, 2021.8As a developing country, India has a five-year grace period to amend its patent laws under the TRIPS Agreement. In other words, the Indian Patents Act 1970 must be amended accordingly by December 31, 1999. The Economic Study (2018-2019) examined the impact of the DPCO on the price and quantity of life-saving medicines. Two drugs, Glycomet and Glimiprex-MF, were taken for comparison. 3This background paper examines the issue of patents and their impact on the pharmaceutical industry in India, whether foreign or Indian companies. DPCO, in 2013, managed to reduce the prices of the most important drugs by retailers and chemists, but affected drugs sold in hospitals. As a result, THE CODD had the opposite effect of what it intended to do. It has increased the prices of the most expensive formulations more efficiently than for the cheapest ones. Developing countries have argued that patent laws could restrict their citizens` access to affordable medicines. They were also unsure of the extent of travel flexibilities and their impact on their rights. In response to these concerns, the JUNE 2001 TRIPS Council systematically addressed the link between public health and TRIPS.
[4] In 1998, Novartis AG, an international pharmaceutical company, filed an application with the Madras Patent Office under the TRIPS Agreement for a patent for a cancer drug called “Glivec”. Even Article 7, which sets out the objectives of the agreement, takes into account the economic and social well-being of the population. It is true that limited exceptions to the exclusive rights conferred by a patent may be provided for as long as the interests of patent holders are not infringed. .